Verastem, Inc. Announces 2024 Annual Meeting of Stockholders on May 23

TL;DR

<b>Verastem, Inc. will hold its 2024 Annual Meeting of Stockholders on May 23, 2024, to elect directors, approve an equity incentive plan, and ratify auditor selection.</b>

AI Summary

Verastem, Inc. (VSTM) filed a Proxy Statement (DEF 14A) with the SEC on April 12, 2024. The 2024 Annual Meeting of Stockholders for Verastem, Inc. will be held on May 23, 2024, at 9:00 a.m. Eastern Time. Stockholders will vote on the election of four Class III directors: Paul Bunn, Anil Kapur, Daniel Paterson, and Michelle Robertson. The meeting agenda includes a vote to approve the Company's Amended and Restated 2021 Equity Incentive Plan. Shareholders will also vote to ratify Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2024. An advisory vote on the compensation of named executive officers and the frequency of future advisory votes will be conducted.

Why It Matters

For investors and stakeholders tracking Verastem, Inc., this filing contains several important signals. The election of directors and approval of the equity incentive plan are critical for the company's governance and future compensation strategies. Ratifying the auditor and holding advisory votes on executive compensation are standard but important governance procedures that impact shareholder confidence.

Risk Assessment

Risk Level: low — Verastem, Inc. shows low risk based on this filing. This filing is a routine proxy statement for an annual meeting and does not contain new financial or operational information that would indicate significant risk.

Analyst Insight

Stockholders should review the director nominees and the proposed equity incentive plan before voting at the Annual Meeting.

Key Numbers

• May 23, 2024 — Annual Meeting Date (Date of the 2024 Annual Meeting of Stockholders.)
• March 26, 2024 — Record Date (Record date for determining stockholders entitled to vote at the Annual Meeting.)
• 2021 — Equity Incentive Plan Year (Year of the equity incentive plan to be voted on.)
• 2024 — Fiscal Year (Fiscal year for which Ernst & Young LLP is proposed as auditor.)

Key Players & Entities

• Verastem, Inc. (company) — Registrant and filer of the proxy statement.
• Paul Bunn (person) — Nominee for Class III director.
• Anil Kapur (person) — Nominee for Class III director.
• Daniel Paterson (person) — Nominee for Class III director.
• Michelle Robertson (person) — Nominee for Class III director.
• Ernst & Young LLP (company) — Proposed independent registered public accounting firm.
• Nasdaq (company) — Stock exchange where Verastem, Inc. common stock is listed.

FAQ

Risk Factors

• Compliance with SEC Regulations [low — regulatory]: The company must comply with all SEC rules and regulations regarding proxy solicitations and annual meetings.
• Director Election and Governance [low — operational]: The election of directors and approval of equity plans are crucial for the company's ongoing governance and ability to attract and retain talent.
• Auditor Ratification [low — financial]: The ratification of the independent auditor is a standard governance procedure that ensures financial reporting integrity.

Key Dates

• 2024-05-23: Annual Meeting of Stockholders — Key date for voting on corporate matters.
• 2024-04-12: Proxy Statement First Made Available — Indicates the start of the proxy voting period.
• 2024-03-26: Record Date — Determines which shareholders are eligible to vote.

Glossary

Proxy Statement

A document filed by a company with the SEC that contains information that shareholders need to make informed decisions about matters presented at a shareholder meeting. (Provides essential details for shareholders to vote on director elections, equity plans, and auditor ratification.)

Key Financial Figures

• $12,500 — ce and information support for a fee of $12,500 plus reasonable out of pocket expenses.
• $0.0001 — and outstanding common stock, par value $0.0001. As a result of the reverse stock split

Filing Documents

• tmb-20240523xdef14a.htm (DEF 14A) — 1385KB
• tmb-20240523xdef14a006.jpg (GRAPHIC) — 34KB
• tmb-20240523xdef14a008.jpg (GRAPHIC) — 1KB
• 0001558370-24-005017.txt (&nbsp;) — 1434KB

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS These proxy materials contain forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "may," "will," "believe," "estimate," "forecast," "goal," "project," and other words of similar meaning. These statements are based on our current expectations and involve risks and uncertainties. Forward-looking statements include, without limitation, statements regarding our ability and effectiveness of our strategies to attract, motivate and retain executives and our expectations that our stockholders will support certain recommendations of our Board of Directors. No forward-looking statement can be guaranteed and actual results may differ materially from those stated or implied by forward-looking statements. We undertake no obligation to publicly update any forward-looking statement, except as required under applicable law. Forward-looking statements should be evaluated together with the many risks and uncertainties that affect our business, particularly those mentioned under the "Risk Factors" heading of our 2023 Annual Report on Form 10-K, as updated by our subsequent filings under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). SPECIAL NOTE On May 31, 2023, we effected a 1-for-12 reverse stock split of our issued and outstanding common stock, par value $0.0001. As a result of the reverse stock split, every 12 shares of issued and outstanding common stock were automatically combined into one issued and outstanding share of common stock, without any change in the par value per share. No fractional shares were issued as a result of the reverse stock split. Stockholders who would otherwise have been entitled to a fractional share of common stock were entitled to receive a price equal to the closing price of the common stock on the Nasdaq Capital Market on the date immediately preceding the effective time of the reverse stock

View Full Filing

View this DEF 14A filing on SEC EDGAR